Boehringer Ingelheim has signed an agreement with Vienna-based f-star to research antibody-derived therapeutic products.
The collaboration is based on f-star’s modular antibody technology, Fcab, and will allow Boehringer Ingelheim to nominate up to seven targets, which could span multiple therapeutic areas.
Go deeper with GlobalData
f-star will receive an initial technology access fee, research-based funding, and is eligible to receive additional licence fees, development, regulatory and commercial milestones, and undisclosed tiered royalties on product sales.
Boehringer Ingelheim can select several therapeutic products from each of seven discovery programs totalling up to a possible €180m if all products are successful.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
